-
Mashup Score: 0
Published in Future Cardiology (Ahead of Print, 2025)
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8An updated AL-base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis - PubMed - 2 month(s) ago
Rarely-observed light chain variable genes may carry a high risk of AL amyloidosis. New approaches are needed to define sequence-associated risk factors for AL amyloidosis. AL-Base is a foundational resource for such studies.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
AL-Base with 2,200 monoclonal light chain sequences from AL amyloidosis & other plasma cell dyscrasias. This is a publicly available dataset. @BU_Amyloidosis https://t.co/aYRP0kn7Y1
-
-
Mashup Score: 10An updated AL-base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis - 2 month(s) ago
Each monoclonal antibody light chain associated with AL amyloidosis has a unique sequence. Defining how these sequences drive amyloid deposition could facilitate faster diagnosis and lead to new tr…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet-
An updated AL-base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis https://t.co/78v04z6AZM
-
-
Mashup Score: 3
We observed favorable OS and EFS after AHSCT for SSc patients, using CY200/ATG, unmanipulated PBSC and MMF post-transplant maintenance, that was comparable to trials with CD34+ graft selection. We identified a possible risk factor, pretransplant low eGFR, for adverse outcome after AHSCT.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Autologous non-myeloablative hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: iden… https://t.co/rN0frXeyPR
-
-
Mashup Score: 16Defying the odds: 30 years in AL amyloidosis research—recent barriers to clinical trial enrollment - 2 month(s) ago
TO THE EDITOR:
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
632 enrollments over 30 years in clinical trials for AL amyloidosis, 8% and 15% racially diverse enrollments in SCT and non-SCT trials. @BU_Amyloidosis Defying the odds: 30 years in AL amyloidosis research—recent barriers to clinical trial enrollment https://t.co/c0nG1SOU79
-
-
Mashup Score: 9Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis - 2 month(s) ago
Background/Objectives: Antibody light chains form amyloid fibrils that lead to progressive tissue damage in amyloid light chain (AL) amyloidosis. The properties of each patient’s unique light chain appear to determine its propensity to form amyloid. One factor is N-glycosylation, which is more frequent in amyloid-associated light chains than in light chains from the normal immune repertoire. However, the mechanisms underlying this association are unknown. Here, we investigate the frequency and position within the light chain sequence of the N-glycosylation sequence motif, or sequon. Methods: Monoclonal light chains from AL amyloidosis and multiple myeloma were identified from the AL-Base repository. Polyclonal light chains were obtained from the Observed Antibody Space resource. We compared the fraction of light chains from each group harboring an N-glycosylation sequon, and the positions of these sequons within the sequences. Results: Sequons are enriched among AL-associated light cha
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet-
No clear structural rationale for why N-glycosylation of κ light chains is associated with AL amyloidosis. @BU_Amyloidosis Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis https://t.co/OVgEk0NZyl https://t.co/HweiyNhEC6
-
-
Mashup Score: 5High-Sensitivity and Conventional Cardiac Troponin-I Assays in AL Amyloidosis - PubMed - 2 month(s) ago
Overall agreement was demonstrated; however, a negative bias for HS-cTnI assay was noted at low concentrations. The application of the conventional cTnI threshold of >100 ng/L to HS-cTnI-based Boston University cardiac staging showed a trend toward downgraded staging assignments. The prognostic u …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
High-Sensitivity and Conventional Cardiac Troponin-I Assays in AL Amyloidosis https://t.co/cBEXo9CuPQ @BU_Amyloidosis
-
-
Mashup Score: 40Defying the Odds: 30 Years in AL Amyloidosis Research, Recent Barriers to Clinical Trial Enrollment - PubMed - 2 month(s) ago
Defying the Odds: 30 Years in AL Amyloidosis Research, Recent Barriers to Clinical Trial Enrollment
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
My journey of 30 years in the clinical research field in a rare disease! @BU_Amyloidosis Defying the Odds: 30 Years in AL Amyloidosis Research, Recent Barriers to Clinical Trial Enrollment https://t.co/bZAI2BBrI3
-
-
Mashup Score: 4High-Sensitivity and Conventional Cardiac Troponin-I Assays in AL Amyloidosis - PubMed - 3 month(s) ago
Overall agreement was demonstrated; however, a negative bias for HS-cTnI assay was noted at low concentrations. The application of the conventional cTnI threshold of >100 ng/L to HS-cTnI-based Boston University cardiac staging showed a trend toward downgraded staging assignments. The prognostic u …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
High-Sensitivity and Conventional Cardiac Troponin-I Assays in AL Amyloidosis https://t.co/cBEXo9CuPQ @BU_Amyloidosis
-
-
Mashup Score: 7
Immunoglobulin light chain amyloidosis (AL) is a life-threatening disease caused by the deposition of light chain (LC) and its fragments containing variable (VL) and portions of constant (CL) domains. AL patients feature either monoclonal free LCs (FLCs) circulating as covalent …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Conformational differences in the light chain constant domain of immunoglobulin G and free light chain may influenc… https://t.co/sYGEPm6U97 @BU_Amyloidosis
-
Current landscape of clinical management for systemic light chain amyloidosis https://t.co/6pNqssqlUr @BU_Amyloidosis @a_staron